BG Medicine, Inc. (BGMD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBG Medicine, Inc. (BGMD) trades at $0.0001. BG Medicine, Inc. is a diagnostics company focused on developing and commercializing cardiovascular diagnostic tests. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for BGMD: BGMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BG Medicine, Inc. (BGMD) Healthcare & Pipeline Overview
BG Medicine, Inc. operates in the medical diagnostics sector, focusing on cardiovascular testing. Their core offerings, the BGM Galectin-3 and CardioSCORE tests, target unmet needs in identifying and managing cardiovascular risks. The company's small size and OTC listing present unique challenges and opportunities in a competitive market.
What Is the Investment Thesis for BGMD?
Investing in BG Medicine, Inc. presents a high-risk, high-reward scenario. The company's focus on cardiovascular diagnostics addresses a significant market need, given the prevalence of heart disease. However, its small market capitalization and OTC listing introduce substantial risks. The BGM Galectin-3 and CardioSCORE tests have the potential to generate revenue, but commercial success hinges on market adoption and reimbursement approvals. With a negative ROE of -902.6% and negative free cash flow, the company's financial stability is a concern. A key value driver is the successful commercialization and adoption of its diagnostic tests. Upcoming catalysts include potential partnerships, regulatory approvals, and expansion into new markets. Investors should carefully weigh the potential upside against the significant financial and operational risks.
Based on FMP financials and quantitative analysis
BGMD Key Highlights
Gross Margin of 67.8% indicates strong potential profitability if sales volume increases.
- Negative ROE of -902.6% reflects significant losses and inefficient use of equity.
- Market Cap of $0.00B indicates the company is a microcap stock with high volatility.
- Free Cash Flow of $-0.00B suggests the company is reliant on external funding.
- Beta of 83.31 indicates extreme volatility relative to the market.
Who Are BGMD's Competitors?
BGMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| A Agilent Technologies, Inc. | $167.77 | +0.65% | $47.4B | 84 5-pillar |
| TMO Thermo Fisher Scientific Inc. | $676.76 | +3.35% | $250B | 67 5-pillar |
| GCTK GlucoTrack, Inc. | $1.11 | -8.26% | — | |
| LUCY Innovative Eyewear, Inc. | $0.89 | -0.21% | $5.61M | — |
| FEMY Femasys Inc. | $2.09 | +1.95% | $6.31M | — |
| RGNT Regentis Biomaterials Ltd. | $1.73 | -6.41% | $12.2M | 64 5-pillar |
| MLSS Milestone Scientific Inc. | $0.36 | -4.23% | $32.0M | — |
| HBIO Harvard Bioscience, Inc. | $8.50 | +1.92% | $38.3M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BGMD's Key Strengths?
Specialized focus on cardiovascular diagnostics.
- Proprietary BGM Galectin-3 and CardioSCORE tests.
- Potential to address unmet medical needs.
- Established presence in the diagnostics market.
What Are BGMD's Weaknesses?
Small market capitalization and OTC listing.
- Negative ROE and free cash flow.
- Limited financial resources.
- Dependence on a small number of products.
What Are the Key Risks for BGMD?
Competition from larger, more established players in the diagnostics market.
- Regulatory hurdles and reimbursement challenges for new diagnostic tests.
- Technological obsolescence of existing diagnostic technologies.
- Limited financial resources and dependence on external funding.
- Small market capitalization and OTC listing increasing volatility.
What Are BGMD's Competitive Advantages?
- Proprietary diagnostic tests: BGM Galectin-3 and CardioSCORE are unique offerings.
- Focus on unmet medical needs: Addressing specific gaps in cardiovascular diagnostics.
- Established presence in cardiovascular testing: Building a reputation in the field.
- Intellectual property: Patents and trademarks protecting their diagnostic technologies.
What Does BGMD Do?
BG Medicine, Inc., established in 2000 and headquartered in Waltham, Massachusetts, is a diagnostics company specializing in the development and commercialization of cardiovascular diagnostic tests. Originally named Beyond Genomics, Inc., the company rebranded in 2004 to reflect its focus on medical solutions. BG Medicine aims to address unmet medical needs through innovative diagnostic tools in the United States, Europe, and internationally. Their primary products include the BGM Galectin-3 test, which measures galectin-3 levels in blood plasma or serum to assess heart failure risk, and the CardioSCORE test, designed to identify individuals at risk of cardiovascular events like heart attack and stroke. The company's diagnostic solutions are intended to aid clinicians in the early detection and management of cardiovascular diseases, a leading cause of mortality worldwide. BG Medicine operates within the broader medical instruments and supplies industry, competing with larger and more established players in the diagnostics market. The company's strategy involves developing and commercializing novel tests that offer improved accuracy and clinical utility compared to existing diagnostic methods.
What Products and Services Does BGMD Offer?
- Develop and commercialize cardiovascular diagnostic tests.
- Offer the BGM Galectin-3 test for assessing heart failure risk.
- Provide the CardioSCORE test for identifying individuals at risk of cardiovascular events.
- Focus on addressing unmet medical needs in cardiovascular disease management.
- Operate in the United States, Europe, and internationally.
- Provide diagnostic tools for early detection and management of cardiovascular diseases.
How Does BGMD Make Money?
- Generate revenue through the sale of diagnostic tests.
- Partner with hospitals and clinics for test utilization.
- Seek reimbursement from insurance companies and healthcare providers.
- Expand market reach through strategic partnerships and international expansion.
What Industry Does BGMD Operate In?
BG Medicine, Inc. operates within the medical instruments and supplies industry, a segment of the healthcare sector characterized by innovation and technological advancements. The cardiovascular diagnostics market is driven by the increasing prevalence of heart disease and the growing demand for early detection and personalized medicine. Competition is intense, with established players like Abbott and Roche dominating the market. BG Medicine, with its niche focus on galectin-3 testing and CardioSCORE, aims to carve out a market share by offering specialized diagnostic solutions. The industry is subject to stringent regulatory requirements and reimbursement policies, which can impact the commercial success of new diagnostic tests.
Who Are BGMD's Key Customers?
- Hospitals and clinics.
- Cardiologists and other healthcare professionals.
- Patients at risk of or diagnosed with cardiovascular diseases.
- Research institutions conducting cardiovascular studies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
BG Medicine, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Stephen Hall. BGMD has traded publicly since 2011.
Financial Health
BG Medicine, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Earnings Track Record
BG Medicine, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 14.7% above estimates on average.
Insider Activity
12 transactions · 0 purchases, 1 sales, 11 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
BGMD Financials
BGMD Latest News
No recent news available for BGMD.
BGMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BGMD.
Price Targets
Wall Street price target analysis for BGMD.
BGMD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BGMD; grades run from A+ (80-100) to F (below 30).
BGMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BG Medicine, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Unlike NYSE or NASDAQ-listed companies, OTC Other firms may not be required to adhere to strict listing standards or maintain a minimum share price.
- OTC Tier: OTC Other
- Limited liquidity and price volatility.
- Lack of regulatory oversight and financial transparency.
- Potential for fraud or manipulation.
- Uncertainty regarding the company's financial condition.
- Limited access to capital markets.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Determine the company's capital structure and funding needs.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Established presence in the diagnostics market.
- Proprietary BGM Galectin-3 and CardioSCORE tests.
- Focus on addressing unmet medical needs.
- Company has been in operation since 2000.
- Headquarters located in Waltham, Massachusetts.
BGMD Healthcare Stock FAQ
What are the main risks for BGMD?
BG Medicine, Inc. faces several key risks. Competition from larger, more established players in the diagnostics market poses a significant threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Financial data is limited and may not be fully up-to-date.